0 84

Cited 1 times in

Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study

Authors
 Chan Woo Wee  ;  Il Han Kim  ;  Chul-Kee Park  ;  Jin Wook Kim  ;  Yun-Sik Dho  ;  Fumiharu Ohka  ;  Kosuke Aoki  ;  Kazuya Motomura  ;  Atsushi Natsume  ;  Nalee Kim  ;  Chang-Ok Suh  ;  Jong Hee Chang  ;  Se Hoon Kim  ;  Won Kyung Cho  ;  Do Hoon Lim  ;  Do-Hyun Nam  ;  Jung Won Choi  ;  In Ah Kim  ;  Chae-Yong Kim  ;  Young-Taek Oh  ;  Oyeon Cho  ;  Woong-Ki Chung  ;  Sung-Hwan Kim  ;  Eunji Kim 
Citation
 Radiotherapy and Oncology, Vol.129(2) : 347-351, 2018 
Journal Title
 Radiotherapy and Oncology 
ISSN
 0167-8140 
Issue Date
2018
Keywords
Glioblastoma ; IDH1 ; MGMT ; Recursive partitioning analysis ; Validation
Abstract
BACKGROUND AND PURPOSE: A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation. The current study was initiated to validate the model in a multi-institutional study. MATERIALS AND METHODS: Four-hundred seventy-one newly diagnosed GBM patients (validation cohort) were allocated to classes I-III of the previously reported GBM-molRPA model. Of the patients, 15.7%, 56.1%, and 28.2% patients were GBM-molRPA class I, II, and III, respectively. MGMTmeth and IDH1mut were observed in 32.3 and 8.8% of patients, respectively. In the training plus validation cohort of 692 patients, 16.2%, 60.8%, and 23.0% patients were class I, II, and III, respectively. RESULTS: The median follow-up for survivors and the median survival (MS) of patients was 23.3 and 18.4 months, respectively. The MS for GBM-molRPA class I, II, and III was 49.7 (95% CI, 22.8-76.6), 19.2 (95% CI, 16.2-22.1), and 13.8 months (95% CI, 11.8-15.4) (P < .001 for all comparisons) in the validation cohort. In the training plus validation cohort, the MS was 58.5 (95% CI, 40.7-76.3), 21. (95% CI, 18.6-23.3), and 14.3 months (95% CI, 12.5-16.1) (P < .001 for all comparisons) for class I, II, and III, respectively. CONCLUSION: The GBM-molRPA is a valid model. This GBM-molRPA classification can be useful in clinics and guiding patient stratification in future clinical trials.
Full Text
https://www.sciencedirect.com/science/article/pii/S0167814018334686
DOI
10.1016/j.radonc.2018.09.001
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Nalee(김나리) ORCID logo https://orcid.org/0000-0003-4742-2772
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Suh, Chang Ok(서창옥)
Chang, Jong Hee(장종희)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/166770
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse